Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long
Starting at the lowest dose and gradually increasing helps minimize side effects, especially digestive and hormonal symptoms
What semaglutide matches well For people who were on lower tirzepatide doses (2.5 to 7.5 mg), semaglutide at appropriate doses can provide nearly equivalent appetite suppression and metabolic benefit
Thanks for joining us, as you know, our purpose, the big reason were here and have a podcast is to help simplify the complexities in our healthcare, economics and policy issues that affect you and the patients and everyone around you